Loading
Life sciences · Journal article
Acs Nano · September 18, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Pancreatic cancer (PC) is a highly lethal malignancy, characterized by frequent late-stage diagnosis and limited response to available treatments. Photoimmunotherapy, which combines the localized tumor ablation of phototherapy with the systemic immune activation of immunotherapy, presents a promising strategy. However, its success is often hampered by insufficient accumulation of therapeutic agents at the tumor site. To address this challenge, we developed a novel antibody-photosensitizer conjugate, named αPD-L1@AIE, by conjugating a multifunctional phototheranostic agent with αPD-L1 antibody for targeted photoimmunotherapy of PC. The incorporation of αPD-L1 not only facilitates tumor-specific targeting but also acts as an immune checkpoint inhibitor. Upon 660 nm laser irradiation, this phototheranostic agent enables NIR-II fluorescence imaging and simultaneously induces potent immunogenic cell death (ICD) via combined photodynamic and photothermal therapy. Following localized phototherapy, the released tumor-associated antigens from ICD initiate a robust antitumor immune response. Such a response is synergistically amplified by αPD-L1, which together alleviates immunosuppression via Treg cell depletion and M2-like macrophage repolarization, thereby promoting a marked increase in cytotoxic T lymphocyte infiltration and granzyme B production. Consequently, the aforementioned photoimmunotherapy approach effectively suppresses tumor growth and inhibits spontaneous metastasis, demonstrating a powerful and transformative paradigm for advanced PC management.